E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Ulcerative colitis (UC) |
Colite ulcerosa (CU) |
|
E.1.1.1 | Medical condition in easily understood language |
Ulcerative colitis |
Colite ulcerosa |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045365 |
E.1.2 | Term | Ulcerative colitis |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of filgotinib in subjects in stable clinical remission on 200 mg filgotinib once daily (q.d.) for whom the dose was decreased to 100 mg q.d. compared to subjects remaining on 200 mg q.d. |
Valutare l’efficacia di filgotinib in soggetti in remissione clinica stabile trattati con 200 mg di filgotinib una volta al giorno (QD) per i quali la dose è stata ridotta a 100 mg QD rispetto ai soggetti che sono rimasti in trattamento con 200 mg QD. |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the effect of dose de-escalation of filgotinib on time to flare. - To evaluate the effect of dose de-escalation of filgotinib on disease-specific biomarkers and Inflammatory Bowel Disease Questionnaire. - To evaluate the safety and tolerability of filgotinib. |
- Valutare l’effetto della riduzione della dose di filgotinib sul tempo alla riacutizzazione. - Valutare l’effetto della riduzione della dose di filgotinib sui biomarcatori specifici della malattia e sul Questionario sulla malattia infiammatoria intestinale (IBDQ). - Valutare la sicurezza e la tollerabilità di filgotinib. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Subjects must be participating in the SELECTION-LTE study, currently on 200 mg filgotinib q.d. and fulfill the following conditions: • pMCS remission over a period of at least 2 consecutive quarterly visits in the SELECTION-LTE study prior to and including screening of the present study; • free of corticosteroids for at least 12 weeks prior to and including baseline; • FCP <=250 µg/g at last observation; • sigmoidoscopy ES of 0 or 1 (local score) at screening. - Female subjects of childbearing potential must have a negative highly sensitive (serum beta human chorionic gonadotropin) pregnancy test during screening and must agree to continued monthly urine dipstick pregnancy testing during filgotinib treatment. - Male subjects and female subjects of childbearing potential must agree to use highly effective contraception measures as defined in the protocol. - Willing to refrain from live attenuated vaccines during the study and for 12 weeks after the last dose of filgotinib in the study.
This list only contains the key inclusion criteria. |
- I soggetti devono star partecipando allo studio SELECTION-LTE, attualmente in terapia con 200 mg di filgotinib QD e soddisfare le seguenti condizioni: • remissione pMCS nell’arco di un periodo di almeno 2 visite trimestrali consecutive nello studio SELECTION-LTE prima del e incluso lo screening del presente studio; • assenza di corticosteroidi per almeno 12 settimane prima del basale incluso; • FCP <=250 µg/g all’ultima osservazione; • sigmoidoscopia ES di 0 o 1 (punteggio locale) allo screening. - I soggetti di sesso femminile in età fertile devono presentare un test di gravidanza altamente sensibile (gonadotropina corionica umana beta sierica) negativo durante lo screening e devono accettare di proseguire con i test di gravidanza urinari con striscia reattiva a cadenza mensile durante il trattamento con filgotinib. - I soggetti di sesso maschile e femminile in età fertile devono accettare di utilizzare misure contraccettive altamente efficaci come definito nel protocollo. - Disponibilità ad astenersi dai vaccini vivi attenuati durante lo studio e per 12 settimane dopo l’ultima dose di filgotinib nello studio.
Questa lista include solo i criteri di inclusione principali. |
|
E.4 | Principal exclusion criteria |
- Any chronic medical condition (including but not limited to, cardiac or pulmonary disease, alcohol, or drug abuse) that, in the opinion of the investigator or sponsor, would make the subject unsuitable for the study or would prevent compliance with the study protocol. - Subject has a known hypersensitivity to filgotinib ingredients or history of a significant allergic reaction to filgotinib ingredients as determined by the investigator. - Female subject who is pregnant or breastfeeding, or intending to become pregnant or breastfeed, and/or plans to undergo egg donation or egg harvesting for the purpose of current or future fertilization, during the study and until the end of the study. - Male subject unwilling to refrain from sperm donation for at least 90 days after the last dose of investigational product. - Subject is unable or unwilling to comply with restrictions regarding prior and concomitant medication as described in the protocol. - Subject has a positive QuantiFERON® tuberculosis (TB) test at screening or subject has 2 indeterminate QuantiFERON® TB test results who require IP treatment interruption. - History of malignancy except for subjects who have been successfully treated for nonmelanoma skin cancer or cervical carcinoma in situ. - Subject meets discontinuation criteria of the SELECTION-LTE study.
This list only contains the key exclusion criteria. |
- Qualsiasi condizione medica cronica (incluso ma non limitato a , malattie cardiache o polmonari, abuso di alcol o sostanze stupefacenti) che, a giudizio dello sperimentatore o dello sponsor, renderebbe il soggetto non idoneo allo studio o ne impedirebbe la conformità al protocollo dello studio. - Il soggetto presenta un’ipersensibilità nota agli ingredienti di filgotinib o un’anamnesi di una reazione allergica significativa agli ingredienti di filgotinib, come determinato dallo sperimentatore. - Soggetto di sesso femminile in gravidanza o allattamento, che intende iniziare una gravidanza o allattare al seno e/o che prevede di sottoporsi a donazione di ovuli o raccolta di ovuli ai fini della fertilizzazione attuale o futura, durante lo studio e fino alla fine dello studio. - Soggetto di sesso maschile non disposto ad astenersi dalla donazione di sperma per almeno 90 giorni dopo l’ultima dose del prodotto sperimentale (IP). - Il soggetto non è in grado o non è disposto a rispettare le restrizioni relative ai farmaci precedenti e concomitanti, come descritto nel protocollo. - Il soggetto presenta un test QuantiFERON® per la tubercolosi (TB) positivo allo screening oppure il soggetto presenta 2 risultati indeterminati del test QuantiFERON® per la TB che richiedono l’interruzione del trattamento con l’IP. - Anamnesi di tumore maligno, fatta eccezione per i soggetti che sono stati trattati con successo per carcinoma cutaneo non melanoma o carcinoma cervicale in situ. - Il soggetto soddisfa i criteri di interruzione dello studio SELECTION-LTE
Questa lista include solo i criteri di esclusione principali. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of subjects in corticosteroid-free clinical remission based on modified Mayo Clinical Score. |
Percentuale di soggetti in remissione clinica senza corticosteroidi1 in base al punteggio della Mayo Clinic modificato. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Time to patient-reported outcome based on 2 items (PRO2) flare. - Time to endoscopic score-confirmed ulcerative colitis flare. - Change from baseline in C-reactive protein and fecal calprotectin. - Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) . - Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious Adverse Events (AEs), and TEAEs leading to treatment discontinuation. |
- Tempo alla riacutizzazione PRO2. - Tempo alla riacutizzazione della colite ulcerosa (CU) confermata mediante punteggio endoscopico (ES). - Variazione rispetto al basale della proteina C-reattiva (CRP) e della calprotectina fecale (FCP). - Variazione rispetto al basale dell’IBDQ. - Frequenza e gravità degli eventi avversi emergenti dal trattamento (TEAE), EA seri emergenti dal trattamento (SAE) e TEAE che portano all’interruzione del trattamento. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Various time points throughout the study as per clinical study design. |
Vari punti temporali durante lo studio secondo il disegno dello studio clinico. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Biomarker assessments |
Valutazione dei biomarcatori |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 62 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
India |
Korea, Republic of |
South Africa |
Taiwan |
United States |
France |
Poland |
Spain |
Switzerland |
Czechia |
Germany |
Italy |
Belgium |
Hungary |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
When the last subject is switched to commercially available filgotinib (i.e. after completing minimum 48 weeks of treatment and the follow-up visit) or, in countries where filgotinib is not commercially available, when the last subject completes 216 weeks in the study. |
Quando l'ultimo soggetto passa a filgotinib disponibile in commercio (cioè dopo aver completato un minimo di 48 settimane di trattamento e la visita di follow-up) o, nei paesi in cui filgotinib non è disponibile in commercio, quando l'ultimo soggetto completa 216 settimane nello studio. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |